@FiercePharma: G7 vows to combat antibiotics resistance, but animal health groups urge caution. More from FierceAnimalHealth | Follow @FiercePharma
@CarlyHFierce: ICYMI: Consumer group demands FDA correct 'compounded mistake' on Vanda's Hetlioz label. Report | Follow @CarlyHFierce
> After shedding a fifth of its workforce in Research Triangle Park, NC, GlaxoSmithKline ($GSK) is trying to lease up to 500,000 square feet of its vacant office space for temporary use by state government employees. More
> Startup Intarcia Therapeutics is aiming to disrupt the diabetes care market with a matchstick-size implant. More
> CVS ($CVS) has agreed to buy Target's ($TGT) pharmacy and clinic business for $1.9 billion. Report
> The federal magistrate recommendation that Kirkland & Ellis--lead takeover counsel for Teva ($TEVA) in its quest to buy Mylan ($MYL)--be thrown off the deal could have major law firms quickly redoing their procedures to avoid risking it happening to them. More
> Researchers from Boston Children's Hospital and Merck ($MRK) are looking into the relationship between social media use and sleep issues, and early findings suggest that patients with sleep disorders may be a greater risk of psychosocial issues. More
Medical Device News
@FierceMedDev: ICYMI Friday: Philips cautions on cardio mortality after ResMed sleep apnea data, intros cardiac imaging tool. Article | Follow @FierceMedDev
@VarunSaxena2: ICYMI Friday: Indian feds stake out plan to become a global hub of device manufacturing and innovation. Story | Follow @VarunSaxena2
@EmilyWFierce: India's PM is facing pushback from MSF over access to generic drugs. More from Reuters| Follow @EmilyWFierce
> FDA approves St. Jude's neurostimulator for Parkinson's, setting up rivalry with Medtronic. Report
> Milestone Pharma raises $17M Series B for Phase II of at-home, drug-device cardiac arrhythmia combo. Story
> Study: Researchers find dual-hormone artificial pancreas best for treating nocturnal hypoglycemia. Article
Biotech News
@FierceBiotech: Briggs Morrison trades lead role in AstraZeneca R&D for the helm of tiny Syndax. News | Follow @FierceBiotech
@JohnCFierce: ICYMI: Bluebird bio builds its case for gene therapy as first sickle cell patient responds. Article | Follow @JohnCFierce
@DamianFierce: Listen to two arguably well-informed people talk about the week in biopharma. FierceBiotech Radio | Follow @DamianFierce
> AstraZeneca spells out key failures for gout drug in PhIII. More
> Israel's RedHill soars as its antibiotic comes through in Phase III. Story
> Avalon, GlaxoSmithKline launch 3 new biotechs with $30M commitment. Article
Animal Health News
> AB Science struggles to break out as canine cancer drug flounders. Report
> Rapamycin raises $2.5M to advance lead drug for treating cancer in pets. Item
> G7 vows to combat antibiotics resistance, but animal health groups urge caution. More
> Scientists scrambling to determine if virulent avian flu is airborne. Story
> Lilly quashes rumors of Elanco spinoff as stock soars. Article
Biotech IT News
> EHR-enabled data dive links stomach blockbusters to heart attacks. More
> Allergan slashes laptop use in full-throttle mobile push. Report
> Takeda taps Sanford for robotics, 3-D modeling skills in heart failure pact. Story
> The search for exceptional responders in tumor sequencing databases. Item
> J&J teams with Emulate to use organ-on-a-chip technology in R&D programs. Article
Pharma Marketing News
> PatientsLikeMe, FDA partner up to track online drug safety clues. Item
> CoheroHealth's 'smart,' mobile spirometer begins pilots with pharma, payers. News
> Experts urge FDA to step in to quash 'Low-T' awareness efforts. More
> Merck ramps up Belsomra marketing, hoping to wake up a sleepy insomnia market. Story
> Mannkind investors skittish after CEO, CFO update on Afrezza launch. Article
And Finally... A new app from a division of Johnson & Johnson ($JNJ) tells you the exact street where the flu and allergies are lurking in your neighborhood. More